Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
Acromegalic patients do not respond with the same degree of growth hormone (GH) inhibition to long-term therapy with the somatostatin analogue SMS 201-995. In order to find a parameter predictive of the effectiveness of the drug, we studied in twelve patients with active acromegaly the relationship between paradoxical GH response to gonadotropin- and thyrotropin-releasing hormone (GnRH and TRH) and GH inhibition after a single standard dose (100 micrograms) of SMS 201-995. Four hours after the subcutaneous injection of the analogue, only those patients who responded to the releasing hormones demonstrated a persistent inhibition of somatotropic cell function. SMS 201-995 appears an effective means for suppressing the elevated GH levels in active acromegaly. Its activity may be more pronounced and its use more beneficial in those patients who react paradoxically to GnRH and TRH.
Candrina
R
R
Cattedra di Clinica medica, Università, Brescia.
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000236:Adenoma / Q000150:complications; D000328:Adult; D005260:Female; D007987:Gonadotropin-Releasing Hormone; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010911:Pituitary Neoplasms / Q000150:complications; D011379:Prognosis; D013973:Thyrotropin-Releasing Hormone
C045210:3-Tyr-octreotide; D007987:Gonadotropin-Releasing Hormone; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D015282:Octreotide